Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy

H Harada*1,2, S Itasaka1, Y Zhu1, L Zeng1,3, X Xie1,3, A Morinibu1, K Shinomiya1 and M Hiraoka1,2

1Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; 2Nano-medicine Merger Education Unit, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; 3Department of Radiation Medicine, Fourth Military Medical University, 17 Charge West Road, Xi’an, Shaanxi 710032, China

Hypoxia-inducible factor-1 (HIF-1) has been reported to promote tumour radioresistance; therefore, it is recognised as an excellent target during radiation therapy. However, the inhibition of HIF-1 in unsuitable timing can suppress rather than enhance the effect of radiation therapy because its anti-angiogenic effect increases the radioresistant hypoxic fraction. In this study, we imaged changes of HIF-1 activity after treatment with radiation and/or an HIF-1 inhibitor, YC-1, and optimised their combination. Hypoxic tumour cells were reoxygenated 6 h postirradiation, leading to von Hippel-Lindau (VHL)-dependent proteolysis of HIF-1α and a resultant decrease in HIF-1 activity. The activity then increased as HIF-1α accumulated in the reoxygenated regions 24 h postirradiation. Meanwhile, YC-1 temporarily but significantly suppressed HIF-1 activity, leading to a decrease in microvessel density and an increase in tumour hypoxia. On treatment with YC-1 and then radiation, the YC-1-mediated increase in tumour hypoxia suppressed the effect of radiation therapy, whereas on treatment in the reverse order, YC-1 suppressed the postirradiation upregulation of HIF-1 activity and consequently delayed tumour growth. These results indicate that treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the therapeutic effect of radiation, and the suppression of the postirradiation upregulation of HIF-1 activity is important for the best therapeutic benefit.

British Journal of Cancer (2009) 100, 747–757. doi:10.1038/sj.bjc.6604939 www.bjcancer.com
Published online 17 February 2009
© 2009 Cancer Research UK

Keywords: radiation therapy; tumour hypoxia; hypoxia-inducible factor-1; molecular imaging

A tumour-specific microenvironment, hypoxia, is associated with resistance to radiation therapy because the depletion of oxygen disturbs radiolysis of H2O and reduces the production of reactive and cytotoxic species, and because radiation-induced DNA damage is fixed and irreparable under normoxia (Thomlinson and Gray, 1955; Brown and Wilson, 2004). In addition to these chemical mechanisms, a biological mechanism mediated by hypoxia-inducible factor-1 (HIF-1) has been reported to play an important role in hypoxia-related radioresistance (Moeller and Dewhirst, 2006).

Hypoxia-inducible factor-1 is a heterodimeric transcription factor composed of an α-subunit (HIF-1α) and a β-subunit (HIF-1β), and its activity is mainly dependent on the stability and modification of the former (Wang et al, 1995). Under normoxic conditions, prolyl hydroxylation and subsequent ubiquitination of the oxygen-dependent degradation (ODD) domain of HIF-1α leads to a rapid degradation of HIF-1α protein with a half-life of 5–8 min (Berra et al, 2001; Jaakkola et al, 2001). On the other hand, HIF-1α is stabilised and interacts with HIF-1β under hypoxic conditions (Wang et al, 1995). The resultant heterodimer, HIF-1, binds to its cognate DNA sequence, the hypoxia-responsive element (HRE), and induces the expression of various factors such as vascular endothelial cell growth factor (VEGF; Norris and Millhorn, 1995; Forsythe et al, 1996; Semenza, 2001). Vascular endothelial cell growth factor has been reported to not only induce angiogenesis but also protect endothelial cells from the cytotoxic effects of irradiation and consequently increase tumour radioresistance (Gorski et al, 1999; Moeller et al, 2004; Zeng et al, 2008). Therefore, targeting HIF-1 is expected to enhance the effect of radiation therapy. Indeed, several pre-clinical studies showed that the inhibition of intratumoral HIF-1 activity with an HIF-1 inhibitor, YC-1, significantly enhanced the therapeutic effect of radiation (Moeller et al, 2004). Likewise, the elimination of HIF-1-positive cells from solid tumours with a protein drug, TOP3, or with a gene therapy strategy had radiosensitising effects (Harada et al, 2002, 2007a; Liu et al, 2007). However, the inhibition of intratumoral HIF-1 activity in unsuitable timing may suppress rather than enhance the effect of radiation therapy; in that the inhibition has an anti-angiogenic effect and consequently increases the radioresistant hypoxic fraction (Yeo et al, 2003). To avoid this, it is important to analyse the relationship between treatment regimen and therapeutic benefit.

In this study, we performed a series of optical and real-time imaging experiments using an HIF-1-dependent reporter gene,
SHRE-ODD-luc (Harada et al., 2007b), and analysed the changes in intratumoral HIF-1 activity after treatment with radiation and/or an HIF-1 inhibitor, YC-1. The imaging experiments revealed that intratumoral HIF-1 activity decreased at 6 h postirradiation, and then increased and peaked at 18–24 h postirradiation. On the other hand, YC-1 temporarily but significantly inhibited HIF-1 activity at 24 h post-injection, leading to a decrease in microvessel density and a resultant increase in tumour hypoxia. We found that the YC-1-mediated increase in the hypoxic fraction has a negative impact on the therapeutic effect of radiation when YC-1 is administered first. On the other hand, in the reverse sequence, YC-1 suppressed the postirradiation activation of HIF-1, leading to an enhancement of radiation therapy. This study emphasises the importance of imaging HIF-1 activity and determining the treatment regimen when combining radiation with an HIF-1 inhibitor.

MATERIALS AND METHODS

Cell culture and reagent

The human cervical epithelial adenocarcinoma cell line (HeLa) was purchased from American Type Culture Collection (Manassas, VA, USA). RCC4/Vector and RCC4/VHL, which are human renal cell carcinoma cell lines (RCC4) stably transfected with pcDNA3 (an empty vector) and pcDNA3-VHL (a VHL-expressing vector), respectively, were purchased from DS Pharma Biomedical (Osaka, Japan). Cells were maintained in 10% FBS-Dulbecco’s modified Eagle’s medium (D-MEM). For normoxic cultures, cells were incubated in a well-humidified incubator with 5% CO2 and 95% air at 37°C. For hypoxic cultures, cells were incubated in a Bactron Anaerobic Chamber, BA TLCITE-2 (O2 < 0.02%; Sheldon Manufacturing Inc., Cornelius, OR, USA). YC-1 (Cayman Chemical Company, Ann Arbor, MI, USA) was dissolved in DMSO at a concentration of 60 mg ml⁻¹.

Isolation of stable transfecants

RCC4/Vector and RCC4/VHL were transfected with the plasmid pSHRE-ODD-luc (Harada et al., 2007b) by the calcium phosphate method (Chen and Okayama, 1987) to establish RCC4/Vector/SHREp-ODD-luc and RCC4/VHL/SHREp-ODD-Luc cells, respectively, and cultured for 10 days in medium containing 400 μg ml⁻¹ of G418 (Nacalai Tesque, Kyoto, Japan). Antibiotic-resistant colonies showing HIF-1-dependent bioluminescence were isolated and established as clones. A representative clone was used in this study. HeLa/EP-Luc and HeLa/SHREp-ODD-Luc cells were established as described earlier (Harada et al., 2005, 2007b).

Luciferase assay for RCC4-derived stable transfecants

Cells were seeded in 24-well plates (2 × 10⁵ cells per well) and cultured under normoxic or hypoxic conditions for 18 h. The cells were washed with PBS twice and lysed with 100 μl of Passive Lysis Buffer (Promega, Madison, WI, USA) for luciferase assays using Luciferase Assay Reagent (Promega) according to the manufacturer’s instructions.

Western blotting, luciferase assay, ELISA and FACS analysis in vitro

HeLa/SHREp-ODD-Luc cells were seeded into six-well culture dish (2 × 10⁶ per well) and treated with HIF-1α siRNA or scramble siRNA (Invitrogen Corp., Carlsbad, CA, USA) for 12 h. The culture medium was refreshed with 1 ml of D-MEM containing 0.1% foetal bovine serum with or without YC-1 (10 μM). The cells were cultured for an additional 24 h under normoxic or hypoxic conditions, and subjected to western blotting with anti-HIF-1α antibody (BD Bioscience, San Diego, CA, USA) and with anti-β-actin antibody (BioVision Research Products, Mountain View, CA, USA) or to luciferase assay (Promega), as described earlier (Harada et al., 2005; Harada et al., 2007b). On the other hand, the normoxic or hypoxic conditional medium was subjected to human VEGF ELISA system (GE healthcare UK Ltd, Buckinghamshire, UK) to analyse the secreted VEGF level, according to the manufacturer’s instructions. The normoxic or hypoxic conditional medium was given to pre-irradiated HUVEC (3 × 10⁵ cells per well in a six-well dish; 2 Gy with an X-ray irradiation (Shimadzu, Kyoto, Japan)), and the HUVEC was cultured for an additional 48 h. Apoptotic fraction (sub-G1 fraction) was analysed with FACS using propidium iodide, as described earlier (Harada et al., 2006).

Tumour-bearing mice and radiation conditions

The suspensions of HeLa-derived cells (2 × 10⁶ cells in PBS) and RCC4-derived cells (2 × 10⁷ cells in PBS) were subcutaneously inoculated into the right hind leg of 6-week-old nude mice (BALB/c nu/nu mice; SHIMIZU Laboratory Supplies Co. Ltd, Kyoto, Japan) and severe combined immunodeficient (SCID) mice (C.B-17/scid/scidJcl; CLEA Japan Inc., Tokyo, Japan), respectively. The tumour xenografts were irradiated with 5 Gy of ³²⁰Cs γ-rays using a Gammacell 40 Exactor (MDS Nordion International Inc., Ontario, Canada). Local irradiation was achieved with a specific collimator (MDS Nordion International Inc.).

Real-time imaging of luciferase activity in tumour xenografts

When the average tumour volume reached approximately 150 mm³, an osmotic pump (model 1007D; Alzet Osmotic Pumps, Cupertino, CA, USA) loaded with 200 μl of o-luciferin (20 mg ml⁻¹ in PBS; Promega) was subcutaneously transplanted into the left flank of tumour-bearing mice. The mice were treated with γ-ray irradiation and/or injected intraperitoneally with YC-1 (100 mg kg⁻¹; see each figure legend for the treatment schedule). Optical imaging to detect luciferase bioluminescence was carried out with an IVIS-200 in vivo imaging device (Xenogen, Alameda, CA, USA). During the imaging, the mice were anaesthetised with 2.5% isoflurane gas in the oxygen flow (1.5 l min⁻¹). Images were analysed using Living Image 2.50-Igor Pro 4.09 software (Xenogen).

Immunohistochemical analyses

HeLa/SHREp-ODD-Luc tumour xenografts were surgically excised 90 min after an intraperitoneal injection with pimonidazole hydrochloride (Natural Pharmacia International Inc., Belmont, MA, USA; 60 mg kg⁻¹). For diaminobenzidine staining of pimonidazole hydrochloride and CD31, the formalin-fixed and paraffin-embedded sections were treated with anti-pimonidazole antibody and anti-CD31 antibody respectively, as described earlier (Harada et al., 2007a; Liu et al., 2007; Zeng et al., 2008). For fluorescent double staining of HIF-1α and pimonidazole, the tumour xenografts were embedded in OCT compound and frozen at −80°C. The frozen sections were fixed in 2% paraformaldehyde and ice-cold methanol sequentially for 5 min each, blocked with blocking solution (serum-free protein block solution (Dako, Glostrup, Denmark) containing 0.1% cold water fish skin (CWFS) gelatin (Sigma-Aldrich Corp., St Louis, MO, USA)) and treated with anti-HIF-1α mAb (BD Bioscience) in the blocking solution. After being washed extensively with PBS, the sections were blocked with PBS containing 0.1% CWFS gelatin and treated with Alexa Fluor 546 rabbit anti-mouse IgG (Invitrogen Corp.) in the blocking solution. After further extensive washing with PBS, counter staining was conducted with DAPI (Wako Pure Chemical Industries Ltd, Osaka, Japan). The sections were next treated with...
FITC-conjugated anti-pimonidazole mAb (Natural Pharmacia International Inc.). For the analysis of perfusion (Hoechst 33342 distribution) and the number of functional blood vessels, tumour-bearing mice were intravenously injected with 100 μl of Hoechst 33342 trihydrochloride trihydrate solution (10 mg ml⁻¹; Invitrogen Corp.) 1 min before excision of each xenograft. To calculate the percentages of pimonidazole-positive and HIF-1α-positive cells, the positive areas were quantified using NIH Image 1.63 software (NIH, Bethesda, MD, USA) and compared with the entire tumour. The quantitative analyses were conducted in a double-blind fashion. To quantify the microvessel density, CD31-positive vessels were counted in 10 fields of five xenografts under ×400 magnifications. The quantitative analyses were conducted in a double-blind fashion.

**Growth delay assay**

The tumour-bearing mice with HeLa/5HREp-ODD-Luc were intravenously injected with YC-1 (100 mg kg⁻¹; see each figure legend for detailed treatment schedule) or its vehicle, and subjected to local γ-ray irradiation (see each figure legend for treatment schedule). The size of solid tumours was measured with calipers.

*Figure 1*  Optical imaging of intratumoral HIF-1 activity after ionising radiation. (A) HeLa/EFp-Luc or HeLa/5HREp-ODD-Luc xenografts were γ-ray irradiated at a dose of 0 or 5 Gy. Intratumoral HIF-1 activity was monitored as luciferase bioluminescence at the indicated time after irradiation. (B) The bioluminescent intensity from the HeLa/EFp-Luc (left) or HeLa/5HREp-ODD-Luc (right) xenograft in (A) was quantified. Shown in the graphs are the profiles of the relative photon count at each time point after irradiation. Results are means ± s.d., n = 6. (C) The HeLa/5HREp-ODD-Luc xenografts were surgically excised at the indicated time after irradiation and subjected to immunohistochemical analyses with anti-HIF-1α mAb (red fluorescence) or anti-Pimonidazole mAb (green fluorescence). Counter staining was conducted with DAPI (blue fluorescence). Bar = 200 μm. (D) Fractions of HIF-1α-positive cells (left) and pimonidazole-positive cells (right) in (C) were quantified. Results are means for 10 fields in five xenografts ± s.d. *P < 0.05, **P < 0.01. (E) The HeLa/5HREp-ODD-Luc xenografts were surgically excised at the indicated time after irradiation and subjected to immunohistochemical analyses with anti-HIF-1α mAb (red fluorescence). A perfusion marker, Hoechst 33342 (blue fluorescence), was administrated i.v. at 1 min before each tumour excision. Bar = 200 μm.
during and after treatments. Tumour volume was calculated as $0.5 \times \text{length} \times \text{width}^2$, and the tumour volume on each day was compared with the initial value to calculate the relative tumour volume.

**Ethics of animal experiments**

All of our animal experiments were approved by the Animal Research Committee of Kyoto University, and the procedures were consistent with the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (second edition).

**RESULTS**

**Changes in intratumoral HIF-1 activity after ionising radiation**

To optimise the combination of radiation and inhibition of HIF-1, we first focused on the dynamics of intratumoral HIF-1 activity after ionising radiation. We performed optical imaging experiments using an HIF-1-dependent reporter gene, 5HREp-ODD-luc, in which the SHRE promoter enhances expression of the ODD-Luc fusion protein under hypoxic conditions (Harada et al., 2007b). As the SHRE promoter depends highly on HIF-1 activity, and because the stability of the ODD-Luc protein is regulated through the same oxygen-dependent mechanism as that of HIF-1, the 5HREp-ODD-luc reporter gene is suitable for the real-time imaging of absolute HIF-1 activity (Harada et al., 2007b). We subcutaneously transplanted HeLa cells stably transfected with the 5HREp-ODD-luc gene (HeLa/5HREp-ODD-Luc cells) and monitored the postirradiation dynamics of intratumoral HIF-1 activity using an optical in vivo imaging device (Figure 1A and B). The level of activity decreased significantly and reached a minimum at 6 h after 5 Gy of $\gamma$-ray irradiation ($P < 0.01$). After that, HIF-1 activity increased, reached a plateau at 18–24 h postirradiation ($P < 0.01$) and decreased thereafter. Immunohistochemical analyses confirmed that the level of HIF-1z protein at the edges of DAPI-positive viable regions correlated with that of bioluminescent intensity in the irradiated HeLa/SHREp-ODD-Luc xenografts (Figure 1C and D, left graph), indicating that the HIF-1z level is mainly responsible for the postirradiation HIF-1 activity in the tumour xenograft. Although the radiation-induced activation of HIF-1 and the underlying mechanisms were reported earlier (Moeller et al., 2004; Harada et al., 2009), this study is the first report to show the temporary decreases in HIF-1z expression and HIF-1 activity at several hours postirradiation.

**pVHL-dependent decrease in HIF-1z protein under radiation-induced reoxygenated conditions**

As HIF-1z is known to be rapidly degraded under oxygen-available conditions (Jaakkola et al., 2001), we postulated that a radiation-induced improvement of oxygen availability (tumour reoxygenation) was involved in the temporary decrease in HIF-1z expression and HIF-1 activity at 6 h postirradiation. To examine this possibility, we performed an immunohistochemical analysis using a marker of hypoxia, pimonidazole (Kennedy et al., 1997; Figure 1C and D). Pimonidazole-positive cells showed almost the same distribution as HIF-1z-positive cells before irradiation (Figure 1C). The numbers of pimonidazole-positive cells predictably decreased 6 h after irradiation (Figure 1C and D, right graph), indicating that radiation-induced reoxygenation occurred in the regions. The distribution of a perfusion marker, Hoechst 33342, among the tumour xenograft was not decreased after radiation treatment, supporting the interpretation that the decrease in pimonidazole-positive cells was caused by the reoxygenation but not by the decrease in permeability of pimonidazole (Figure 1E).

We postulated that the temporary downregulation of HIF-1 activity resulted from the pVHL-dependent proteolysis of HIF-1z protein under reoxygenated conditions. To test this possibility, we took advantage of a VHL-deficient human renal cell carcinoma cell line RCC4. RCC4 cells stably transfected with the 5HREp-ODD-luc

![Figure 2](image-url)
reporter gene (RCC4/Vector/5HREp-ODD-Luc cells) showed intense bioluminescence regardless of the surrounding conditions in vitro (Figure 2A). On the other hand, reconstitution of the functional VHL gene (RCC4/VHL/5HREp-ODD-Luc cells) resulted in hypoxia-dependent bioluminescence (Figure 2A). We subcutaneously transplanted the cells and monitored the dynamics of intratumoral HIF-1 activity after 5 Gy of γ-ray irradiation (Figure 2B and C). We chose a SCID mouse as described earlier, because it was difficult to prepare RCC4 tumour xenografts in nude mice (Ogura et al, 2005). The HIF-1 activity in the RCC4/Vector/5HREp-ODD-Luc tumour xenograft did not decrease 6 h after irradiation but gradually increased and peaked at 24 h after irradiation. On the other hand, RCC4/VHL/5HREp-ODD-Luc xenografts showed the same pattern as HeLa/5HREp-ODD-Luc xenografts. These results clearly showed that radiation-induced reoxygenation leads to the degradation of HIF-1α protein through a pVHL-dependent pathway 6 h after irradiation.

Changes in intratumoral HIF-1 activity after administration of an HIF-1 inhibitor, YC-1

We next evaluated the effect of an HIF-1 inhibitor, YC-1, on the intratumoral HIF-1 activity with the same optical imaging experiment (Figure 3A and B). Hypoxia-inducible factor-1 activity gradually but significantly decreased and reached a minimum of 24 h after the administration of YC-1 in the HeLa/5HREp-ODD-Luc tumour xenograft (P<0.01). The activity then recovered to the same levels as in vehicle-injected tumours until 48 h post-injection. Immunohistochemical analysis for HIF-1α protein confirmed that the level of HIF-1α protein at the edges of DAPI-positive viable regions was dramatically decreased 24 h after the YC-1 treatment and correlated with the intensity of bioluminescence detected with the imaging device (Figure 3C and D).

YC-1-mediated increase in tumour hypoxia suppresses the therapeutic effect of radiation

As HIF-1 is known as a master regulator of angiogenesis, we assumed that the inhibition of intratumoral HIF-1 activity would influence the distribution and proportion of tumour hypoxia. To examine this possibility, we performed immunohistochemical analyses of CD31 (for tumour blood vessels) and pimonidazole hydrochloride (for tumour hypoxia). The YC-1-mediated HIF-1 inhibition led to a significant decrease in microvessel density (Figure 4A and B; P<0.05) and resultant increase in hypoxic fractions (Figure 4C and D) at 120 h (5 days) after the YC-1 treatment.

As hypoxia has been associated with the radioresistance of tumours, we speculated that the YC-1-mediated increase in hypoxia might suppress the cytotoxic effect of radiation. To
Optimisation of radiation and HIF-1-targeting therapy

To further confirm the importance of HIF-1 inhibition 24 h postirradiation, we performed the same kind of experiments with a different regimen (Figure 6). YC-1 was administered 18 h before irradiation (Figure 6A) with the expectation that the maximum HIF-1-inhibiting effect led to a delay of tumour growth compared with the radiation therapy alone (Figure 5D). Tumour growth doubling times after ‘the IR treatment alone’ and ‘the combination with +1 min interval’ were ‘26.5 ± 5.4 days’ and ‘36.5 ± 5.5 days’, respectively (Table 1; \( P < 0.05 \)).

Table 1 Statistical analysis of TGDT

| Treatment | Figure 4 (−5 days) | Figure 5 (+1 min) | Figure 6 (−18h) |
|-----------|---------------------|-------------------|-----------------|
| Sham      | 10.0 ± 3.1          | 4.8 ± 1.9         | 8.0 ± 3.9       |
| YC-1      | 12.2 ± 3.6\(^*\)    | 5.1 ± 2.1\(^*\)   | 9.3 ± 3.4\(^*\) |
| RT        | 41.4 ± 6.8          | 26.5 ± 5.4        | 27.7 ± 6.4      |
| Combination | 33.8 ± 5.4\(^*\) | 36.5 ± 5.5\(^*\) | 30.8 ± 5.5\(^*\) |

TGDT = tumour growth doubling time. NS1, not significant vs Sham group; NS2, not significant vs RT group. TGDT was calculated as the mean of the days in which relative tumour volume of each tumour reached two-fold of the volume on day 0. Data were based on the results of the growth delay assays in Figures 4–6. Results are the mean of the days after YC-1 treatment ± s.d. (n = 8). \(^*\) \( P < 0.05 \) vs RT group.

on the therapeutic effect of radiation in such an unsuitable treatment regimen.

Suppression of postirradiation HIF-1 activation sensitises the effect of radiation therapy

To find the optimal regimen, we next examined whether the suppression of HIF-1 activation 24 h postirradiation improves the therapeutic effect of radiation. As a maximal effect of YC-1 on HIF-1 activity was observed 24 h after its administration (Figure 3A and B), we administered YC-1 just after (at 1 min after) radiation treatment to effectively suppress the upregulation of HIF-1 activity at 24 h postirradiation (Figure 5A). Optical imaging experiments confirmed that the administration almost completely suppressed the radiation-induced upregulation of HIF-1 activity (Figure 5B and C; \( P < 0.01 \)). The HIF-1-inhibiting effect led to a delay of tumour growth compared with the radiation therapy alone (Figure 5D). Tumour growth doubling times after ‘the IR treatment alone’ and ‘the combination with +1 min interval’ were ‘26.5 ± 5.4 days’ and ‘36.5 ± 5.5 days’, respectively (Table 1; \( P < 0.05 \)).

To further confirm the influence of HIF-1 inhibition 24 h postirradiation, we performed the same kind of experiments with a different regimen (Figure 6). YC-1 was administered 18 h before radiation (Figure 6A) with the expectation that the maximum HIF-1-inhibiting effect of YC-1 would come 6 h postirradiation, at which time radiation-induced reoxygenation minimised the intratumoral HIF-1 activity through a VHL-dependent mechanism (Figures 1 and 2). The optical imaging experiments confirmed that the decrease in HIF-1 activity caused by YC-1 and by the radiation overlapped each other at 6 h postirradiation, and YC-1 had no influence on the upregulation of HIF-1 activity at 24 h.

examine such a possibility, we treated the HeLa/SHREp-ODD-Luc tumour xenografts with radiation 120 h (5 days) after YC-1 treatment (Figure 4E), and performed a tumour growth delay assay (Figure 4F). The single administration of YC-1 alone little influenced tumour growth compared with vehicle treatment (Figure 4F and Table 1), although it led to a significant decrease in microvessel density (Figure 4A and B). However, YC-1 treatment accelerated rather than delayed tumour growth after radiation therapy, when it was administered 120 h (5 days) before the radiation treatment (Figure 4F). Days, in which tumour volume reached two-fold of the initial volume (tumour growth doubling time), after ‘the IR treatment alone’ and ‘the combination with −5 days interval’ were ‘41.4 ± 6.8 days’ and ‘33.8 ± 5.4 days’, respectively (Table 1; \( P < 0.05 \)). These results indicate that the YC-1-induced increase in tumour hypoxia protects tumour cells against radiation, and HIF-1 inhibitors have a negative impact

Figure 4 YC-1-mediated increase in tumour hypoxia suppresses the therapeutic effect of radiation. (A–D) The HeLa/SHREp-ODD-Luc xenografts were surgically excised 120 h (5 days) after the administration of vehicle or YC-1, and subjected to immunohistochemical analysis with anti-CD31 mAb (A) or anti-pimonidazole Ab (C), Bar = 50 μm. Microvessel density detected as CD31-positive cells in (A) and hypoxic cells detected as pimonidazole-positive cells (right) in (C) were quantified in (B) and (D), respectively. Results are means for 10 fields in five xenografts ± s.d. \( \ast \) \( P < 0.05 \). (E) Treatment schedule of YC-1 and radiation therapy. The HeLa/SHREp-ODD-Luc tumour-bearing mice were administered with vehicle (Sham and RT groups) or YC-1 (YC-1 and Comb groups) on day 0, and subjected to (Sham and YC-1 groups) or 5 Gy (RT and Comb groups) of γ-ray irradiation on day 5. (F) Growth delay assay after the treatment described in (E). Relative tumour volumes are calculated as the ratio of the tumour volume on each day to the corresponding volume on day 0. Results are the means for eight independent tumours ± s.d.
postirradiation with this regimen (Figure 6B and C). The administration of YC-1 had almost no impact on the therapeutic effect of radiation with this regimen (Figure 6D). Tumour growth doubling times after ‘the IR treatment alone’ and ‘the combination and radiation alone’ were ‘27.7 ± 6.4 days’ and ‘30.8 ± 5.5 days’, respectively (Table 1; no significant difference between the combination and radiation alone). These results indicate that YC-1 has a radiosensitising effect only when administered to suppress the radiation-induced activation of HIF-1.

YC-1 enhances the vascular-disrupting effect of radiation in optimal treatment regimen

It has been reported that HIF-1 becomes active in response to radiation-induced alteration of tumour microenvironment, induces VEGF and consequently protects endothelial cells from the cytotoxic effect of radiation (Gorski et al., 1999; Moeller et al., 2004; Zeng et al., 2008). On the basis of this information, we hypothesised that YC-1 has a potential to enhance the vascular-disrupting activity of radiation through the suppression of HIF-1 activity. To examine such a possibility in vitro, we cultured the HeLa/SHReEp-ODD-Luc cells under normoxic or hypoxic conditions and obtained each conditional medium. The conditional medium was given to pre-irradiated (2 Gy of X-ray) HUVEC, and their apoptotic fraction was quantified as sub-G₁ fraction with FACS analysis (Figure 7). The hypoxic treatment for 24h was sufficient to induce HIF-1α expression (Figure 7A, upper lane 3) and HIF-1 activity (Figure 7A, lower lane 3; *P < 0.01) in the HeLa/SHReEp-ODD-Luc cells. The hypoxic conditional medium contained a higher concentration of a hypoxia-dependent gene product secreted from the HeLa/SHReEp-ODD-Luc cells (compare Figure 7B lane 1 with 3; *P < 0.01) and significantly protected the HUVEC from radiation-induced apoptosis compared with the normoxic counterpart (compare Figure 7C lane 5 with 7; *P < 0.05). The HIF-1α siRNA treatment suppressed the hypoxia-dependent expression of HIF-1α (compare Figure 7A, upper lane 5 with 6), activation of HIF-1 (compare Figure 7A, lower lane 5 with 6; *P < 0.01) and secretion of VEGF (compare Figure 7B lane 5 with 6). Consequently, the HIF-1α siRNA treatment suppressed the radioprotective effect of the hypoxic conditional medium (compare Figure 7C lane 9 with 10). YC-1 also suppressed the radioprotective effect of hypoxic conditional medium through the decrease in HIF-1α expression, HIF-1 activity and VEGF secretion (Figure 7).

To examine whether such an effect of YC-1 was responsible for the best therapeutic benefit of our optimal treatment regimen in Figure 5, we performed immunohistochemical analyses for functional blood vessels and for tumour hypoxia (Figure 8) at 5 days after ionising radiation of each treatment regimen applied in Figures 4–6 (Figure 8A). When we administered YC-1 at 1 min after radiation treatment and suppressed the postirradiation
DISCUSSION

In this study, we performed optical imaging experiments and revealed that ionising radiation induces dynamic changes in intratumoral HIF-1 activity: a temporary decrease and a subsequent increase. In addition, the imaging revealed that YC-1 treatment temporarily inhibits intratumoral HIF-1 activity, leading to a decrease in tumour microvessel density and resultant increase in the tumour hypoxic fraction. On the basis of these results, we set treatment regimens combining radiation with YC-1, and compared their therapeutic efficacy. Finally, we revealed that treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the therapeutic effect of radiation and that the suppression of the postirradiation upregulation of HIF-1 activity is important for the best therapeutic benefit.

The reason why such dynamics (especially the temporary decrease) of HIF-1 activity after radiation had not been observed before seemed to be differences in experimental strategy. To date, HIF-1 expression in tumour xenografts has been mainly analysed immunohistochemically. However, it is impossible to follow changes in expression sequentially in individual living animals. Moreover, an alternative strategy using conventional SHRep-GFP or SHRep-luc genes was unsuitable for real-time imaging because the stability of the reporter proteins made it difficult to reflect rapid decreases in HIF-1 activity (Liu et al., 2005; Harada et al., 2007b). To overcome these problems, we applied here an HIF-1-dependent reporter gene, SHRep-ODD-luc (Harada et al, 2007b).

As the stability of the ODD-Luc fusion protein is regulated through the same oxygen-dependent mechanism as that of HIF-1α protein, the reporter gene enabled us to perform the imaging of absolute HIF-1 activity in real time. Therefore, we could show here that intratumoral HIF-1 activity initially decreases several hours after irradiation and then increases thereafter. Applying the imaging system to a VHL-deficient RCC4 cell line, we could identify the PHD-VHL pathway as critical to the temporary decrease in HIF-1 activity after radiation.

Knockdown of HIF-1α protein almost completely inhibited the expression of HIF-1α under hypoxic conditions (Figure 7A, upper lane 6), resulting in about 90% suppression of the SHRep-ODD-luc

upregulation of HIF-1 activity, the number of functional microvessel was significantly decreased (Figure 8Bd and C) and the pimonidazole-positive fraction was significantly increased (Figure 8Bd and D) compared with those after the other two combination regimens. These results suggest that, in the optimal treatment regimen, YC-1 enhanced the therapeutic effect of radiation through (1) suppressing radiation-induced HIF-1α expression and HIF-1 activity, (2) suppressing HIF-1-dependent secretion of radioprotective protein(s) such as VEGF, (3) increasing radiosensitivity of endothelial cells and (4) decreasing microvessel density.

Figure 6  Unsuitable timing of YC-1 administration has no influence on therapeutic effect of radiation. (A) Treatment schedule of YC-1 and radiation therapy. The HeLa/SHRep-ODD-Luc tumour-bearing mice were administered with vehicle (Sham and RT groups) or YC-1 (YC-1 and Comb groups), and the xenografts were subjected to 0 (Sham and YC-1 groups) or 5 Gy (RT and Comb groups) of γ-ray irradiation 18 h later. (B) Intratumoral HIF-1 activity was measured as luciferase bioluminescence at the indicated time after irradiation. (C) The bioluminescence detected in (B) was quantified. Shown in the graphs are the profiles of the relative photon count at each time point after the irradiation. Results are means ± s.d., n = 8. *P < 0.05. (D) Growth delay assay after the treatment described in (A). Relative tumour volumes are calculated as the ratio of the tumour volume on each day to the corresponding volume on day 0. Results are the means for eight independent tumours ± s.d. Time after the administration of YC-1 is given in parentheses.
sub-G1 fraction. All results are means of conditional mediums for 48 h. The apoptotic fraction was quantified as led to the same results as the HIF-1 conditional medium on endothelial cells in vitro. YC-1 diminishes the radioprotective effect of hypoxic postirradiation reoxygenation that radiation-induced damage of residual DNA double-strand breaks within normoxic tumour cells. Bristow and Hill (2008) reported that there is an increase in microvessel density in solid tumours. Moreover, YC-1 treatment at 48 h post-irradiation although HIF-1 activity was upregulated at 24 h postirradiation, there was no significant difference in the intratumoral HIF-1 activity between ‘irradiated group’ and ‘non-irradiated group’ in the latter time points (48, 72, 96 and 120 h postirradiation), indicating that the YC-1 treatment has not only an additional crucial mechanism in the upregulation (Harada et al, 2009). The relationship between the ROS-related stabilisation and the glucose- and Akt/mTOR-related translation of HIF-1-z protein as an additional crucial mechanism in the upregulation (Harada et al, 2009). The relationship between the ROS-related stabilisation and the glucose- and Akt/mTOR-related translation of HIF-1-z protein alone could not be fully responsible for the activation of HIF-1 without newly translated HIF-1-z, and both the mechanisms function coordinately in the induction of HIF-1 activity after irradiation in vivo. Our optical imaging experiments visualised the target specificity of an HIF-1 inhibitor, YC-1: treatment with YC-1 led to a decrease in microvessel density in solid tumours. Such an activity resulted in a decrease in tumour hypoxia 5 days after the administration of YC-1 in our experimental setting. The YC-1-mediated increase in tumour hypoxia had a negative impact on the effect of radiation therapy and accelerated tumour growth after the therapy, when it was administered 5 days before the irradiation. This result is reasonable in terms of the ‘oxygen effect theory’ (Brown and Wilson, 2004), although YC-1 targeting has been reported to be a promising strategy for enhancing the effect of radiation. In addition to the therapy, suppression of ATP metabolism, proliferation and p53 activation by the inactivation of HIF-1 in this time course might have been responsible for the negative impact of YC-1 on the effect of radiation therapy, as has been reported earlier (Moeller et al, 2005). On the other hand, when administered at a time suitable to suppress the postirradiation upregulation of HIF-1 activity, YC-1 dramatically enhanced the therapeutic effect of radiation and significantly delayed tumour growth compared with radiation therapy alone. Our in vitro and in vivo experiments revealed the mechanism responsible for the radioenhancing effect of an HIF-1 inhibitor through the suppression of radiation-induced HIF-1-z expression and HIF-1 activity, decrease in HIF-1-dependent secretion of proangiogenic protein(s) such as VEGF, increase in radiosensitivity of endothelial cells and decrease in microvessel density. This interpretation is well consistent with the earlier reports (Gorski et al, 1999; Moeller et al, 2004; Zeng et al, 2008).

Although we have shown here the importance of suppressing intratumoral HIF-1 activity after radiation therapy, we should pay attention to the other possibility. It was reported earlier that YC-1 suppresses HIF-1-z accumulation through the inhibition of various signalling pathways, including PI3K/Akt/mTOR/4E-BP and NF-kappaB (Sun et al, 2007). In addition, YC-1 is known to have an interesting property arresting cell cycle at S phase and inducing apoptosis in hypoxic cells (Yeo et al, 2006). The difference in the therapeutic effect of three treatment regimens therefore may depend on such YC-1 properties as well as on the ‘oxygen effect theory’. Considering the vascular-disrupting effect of radiation therapy, we hypothesised that recurrent tumour may be hypoxic and HIF-1 active. If it is true, postirradiation YC-1 treatment should enhance the therapeutic effect of radiation. However, in our experimental setting, there was no significant difference in the intratumoral HIF-1 activity between ‘irradiated group’ and ‘non-irradiated group’ in the latter time points (48, 72, 96 and 120 h postirradiation), although HIF-1 activity was upregulated at 24 h postirradiation (data not shown). Moreover, YC-1 treatment at 48 h post-irradiation had no radioenhancing effect (data not shown). These results are not consistent with the above-mentioned speculations;

---

Figure 7 YC-1 diminishes the radioprotective effect of hypoxic conditional medium on endothelial cells in vitro. HeLa/SHRep-ODD-Luc cells were treated with HIF-1-z-siRNA or Scramble (Scr)-siRNA or without both of them (−), and cultured under normoxic (N) or hypoxic (H) conditions in the presence (++) or absence (−−) of YC-1. (A) The Hela/SHRep-ODD-Luc lysates were subjected to western blotting for HIF-1 (upper) or β-actin (middle) and to luciferase assay (lower). (B) The conditional mediums of the HeLa/SHRep-ODD-Luc cells were subjected to ELISA for VEGF level. The VEGF level after each treatment was compared with that after normoxic, YC-1 (−) and siRNA (−) conditions. (C) HUVEC was X-ray irradiated (2 Gy) and cultured in the above conditional mediums for 48 h. The apoptotic fraction was quantified as sub-G1 fraction. All results are means ± s.d., n = 3, *P < 0.05, **P < 0.01.

---

reporter gene activity (Figure 7A, lower lane 6). Moreover, YC-1 led to the same results as the HIF-1-z knockdown (Figure 7A, lane 4). These results confirmed the specificity of the SHRep-ODD-luc reporter gene and YC-1 to HIF-1. Immunohistochemical analysis using a marker of hypoxia revealed that the radiation-induced reoxygenation continued until 24 h postirradiation. In addition, we have confirmed that radiation efficiently induced apoptosis of normoxic tumour cells surrounding tumour blood vessels (data not shown). Moreover, Bristow and Hill (2008) reported that there is an increase in residual DNA double-strand breaks within normoxic tumour regions (indicated by an increased 53BP1 nuclear foci). These results are consistent with a well-known model underlying postirradiation reoxygenation that radiation-induced damage of tumour cells surrounding tumour blood vessels leads to the decrease in oxygen consumption in these regions and an increase in oxygen availability in hypoxic tumour cells.

---

Optimisation of radiation and HIF-1-targeting therapy
H Harada et al
British Journal of Cancer (2009) 100(5), 747 – 757

---

© 2009 Cancer Research UK
however, they support our opinion that the suppression of postirradiation upregulation of HIF-1 activity is most important for the best therapeutic benefit.

This study raises the important possibility that other strategies that lead to an increase in tumour hypoxia might have the same negative influence on the therapeutic effect of radiation as YC-1. This might be true of anti-angiogenic agents and anti-vascular agents as well as other HIF-1-targeting therapeutics. Although it has been confirmed that anti-angiogenic agents enhance the effect of radiation therapy in various basic and clinical studies, the benefit might further be increased by optimising the regimen using an HIF-1 imaging strategy. As HIF-1 activity is not fully dependent on hypoxia, HIF-1-positive cells do not necessarily overlap with absolute hypoxic regions. From this point of view, it is necessary to develop a strategy to assess intratumoral HIF-1 activity in real time, in addition to the development of methods to assess absolute hypoxia.

ACKNOWLEDGEMENTS

This study was part of the programme ‘R&D of Molecular Imaging Equipment for Malignant Tumor Therapy Support’ supported by New Energy and Industrial Technology Development Organization (NEDO) Japan. This study was supported by grants-in-aid for Scientific Research on Priority Areas (Cancer Research) and for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

REFERENCES

Berra E, Roux D, Richard DE, Pouyssegur J (2001) Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2:615–620
Bristow RG, Hill RP (2008) Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180–192
Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447
Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745–2752
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Maurer HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR (1999) Blockade of the vascular endothelial growth factor stress response...
increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374 – 3378
Harada H, Hiraoka M, Kizaka-Kondoh S (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013 – 2018
Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M (2009) The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem doi/10.1074/jbc.M806653200 (in press)
Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182 – 193
Harada H, Kizaka-Kondoh S, Hiraoka M (2006) Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett 580: 5718 – 5722
Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M (2007b) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791 – 796
Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M (2007a) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26: 7508 – 7516
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468 – 472
Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, Varia MA (1997) Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays, Int J Radiat Oncol Biol Phys 37: 897 – 905
Liu J, Harada H, Ogura M, Shibata T, Hiraoka M (2007) Adenovirus-mediated hypoxia-targeting cytotoxic deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer 96: 1871 – 1878
Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M (2005) Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 46: 93 – 102
Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 249 – 241
Moeller BJ, Dewhirst MW (2006) HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1 – 5
Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW (2005) Pleiotropic effects of HIF-1 blockade on tumor radio-sensitivity. Cancer Cell 8: 99 – 110
Norris ML, Millhorn DE (1995) Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. J Biol Chem 270: 23774 – 23779
Ogura M, Shibata T, Yi J, Liu J, Qu R, Harada H, Hiraoka M (2005) A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Sci 96: 288 – 294
Semenza GL (2001) HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107: 1 – 3
Sun HL, Liu YN, Huang YT, Pan SI, Huang DY, Guh JH, Lee FY, Kuo SC, Teng CM (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26: 3941 – 3951
Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539 – 549
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510 – 5514
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516 – 525
Yeo EJ, Ryu JH, Chun YS, Cho YS, Jang IJ, Cho H, Kim J, Kim MS, Park JW (2006) YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 66: 6345 – 6352
Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, Kizaka-Kondoh S, Morinibu A, Shinomiya K, Hiraoka M (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99: 2327 – 2335